Protagenic Therapeutics Inc (NASDAQ:PTIX) shares, rose in value, with the stock price up by 5.87% to the previous day’s close as strong demand from buyers drove the stock to $0.35.
Actively observing the price movement in the recent trading, the stock is buoying the session at $0.33. Referring to stock’s 52-week performance, its high was $1.87, and the low was $0.24. On the whole, PTIX has fluctuated by 5.55% over the past month.
With the market capitalization of Protagenic Therapeutics Inc currently standing at about $2.56 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PTIX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PTIX currently trading nearly 25.92% and -10.54% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.85, while the 7-day volatility ratio is showing 26.15% which for the 30-day chart, stands at 13.26%. Furthermore, Protagenic Therapeutics Inc (PTIX)’s average true range (ATR) is 0.05.
A comparison of Protagenic Therapeutics Inc (PTIX) with its peers suggests the former has fared considerably weaker in the market. PTIX showed an intraday change of 5.87% in today’s session so far, and over the past year, it shrunk by -66.32%%. On the other hand, the price of Alphabet Inc. Cl A (GOOGL) has risen 1.23%% today. The stock, however, is off 28.75% from where it was a year ago.
Data on historical trading for Protagenic Therapeutics Inc (NASDAQ:PTIX) indicates that the trading volumes over the past 3 months, they’ve averaged 2.16 million. According to company’s latest data on outstanding shares, there are 7.24 million shares outstanding.
Nearly 13.43% of Protagenic Therapeutics Inc’s shares belong to company insiders and institutional investors own 5.38% of the company’s shares. The stock has fallen by -27.84% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PTIX stock heading into the next quarter.
